Suppr超能文献

与成人囊性纤维化患者下一次肺部恶化时间缩短相关的因素。

Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.

机构信息

Department of Respiratory Medicine, Bristol Royal Infirmary, Bristol, UK.

出版信息

Chron Respir Dis. 2012 Feb;9(1):9-16. doi: 10.1177/1479972311433575.

Abstract

Time until the subsequent exacerbation (PEx) in cystic fibrosis (CF) is a significant health outcome and one of the significant end points in clinical trials. Risk factors associated with shorter time until the next exacerbation (TUNE) have not been reported. This is a prospective study. TUNE was the number of days from the end of intravenous (IV) antibiotic treatment of a PEx until the day of start of IV antibiotics for the following PEx. Factors assessed were age, gender, site of treatment, CF-related diabetes (CFRD), allergic bronchopulmonary aspergillosis (ABPA) and infection with Pseudomonas aeruginosa (PA). In addition, we examined parameters obtained at day 14 of treatment including forced expiratory volume in the first second (FEV1), body mass index, CF respiratory symptom score, C-reactive protein (CRP) and serum cytokines. A total of 170 exacerbations in 58 adult CF patients (27 female), mean (SD) age 25.8 (6.7) years were analysed. When analysing individual variables, patients with lower FEV1, greater symptom score and higher CRP at the end of exacerbation were associated with shorter TUNE. Patients with ABPA and CFRD had a shorter TUNE than those without. When applying multiple regression analysis, factors associated with shorter TUNE were older age and lower day-14 FEV1 values. Shorter periods until the following PEx are expected in older CF patients and those with lower FEV1 at the end of course of treatment. When these risk factors are present, there may be a justification to take therapeutic steps to increase the time until the following PEx.

摘要

在囊性纤维化 (CF) 中,下一次加重 (PEx) 的时间是一个重要的健康结果,也是临床试验中的重要终点之一。与下一次加重 (TUNE) 时间缩短相关的危险因素尚未报道。这是一项前瞻性研究。TUNE 是从 PEx 的静脉内 (IV) 抗生素治疗结束到下一次 PEx 开始 IV 抗生素治疗的天数。评估的因素包括年龄、性别、治疗部位、CF 相关糖尿病 (CFRD)、过敏性支气管曲霉病 (ABPA) 和铜绿假单胞菌 (PA) 感染。此外,我们还检查了治疗第 14 天获得的参数,包括第一秒用力呼气量 (FEV1)、体重指数、CF 呼吸症状评分、C 反应蛋白 (CRP) 和血清细胞因子。共分析了 58 例成年 CF 患者 (27 名女性) 的 170 次加重,平均 (SD) 年龄为 25.8 (6.7) 岁。在分析单个变量时,在加重结束时 FEV1 较低、症状评分较高和 CRP 较高的患者与 TUNE 缩短有关。患有 ABPA 和 CFRD 的患者比没有 ABPA 和 CFRD 的患者 TUNE 更短。在应用多元回归分析时,与 TUNE 缩短相关的因素是年龄较大和第 14 天 FEV1 值较低。在 CF 患者中,年龄较大和治疗结束时 FEV1 较低的患者预计会更早出现下一次 PEx。当存在这些危险因素时,可能有理由采取治疗措施来延长下一次 PEx 的时间。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验